Synta names new CEO
This article was originally published in Scrip
Executive Summary
Synta Pharmaceuticals, a biopharmaceutical company developing small-molecule drugs for severe medical conditions, including cancer and chronic inflammatory diseases, has named Anne Whitaker chief executive officer – effective 2 September 2014. Ms Whitaker will also become a member of the company's board of directors. She joins Lexington, Massachusetts-based Synta from Sanofi, where most recently she was president of its North American pharmaceuticals unit.